Answers are grounded in this paper and cite their sources.
Background Temozolomide (TMZ) resistance in glioblastoma (GBM) is largely driven by enhanced DNA repair, but the contribution of mitochondrial metabolism and post-translational modifications remains unclear. Methods Integrated multi-omics were performed on TMZ-sensitive and resistant GBM cells. Succinylation sites were mapped by mass spectrometry; the succinyltransferase was identified via co-IP and in vitro assays. Mechanistic studies used mutagenesis, ubiquitination/degradation assays, and homologous recombination (HR) reporters. Pharmacological inhibition and a natural compound disrupting CPT1A–RAD51 were tested in orthotopic xenografts. Clinical relevance was evaluated in two patient cohorts. Results Resistant cells exhibited elevated α-ketoglutarate and succinate, expanding the succinyl-CoA pool. This rewiring drove RAD51 succinylation at K156, catalyzed by CPT1A—a novel succinyltransferase. K156 succinylation antagonized STUB1-dependent K48-linked ubiquitination at K216, protecting RAD51 from degradation and enhancing HR repair. CPT1A inhibition reduced RAD51 succinylation, impaired DNA repair, and restored TMZ sensitivity in vitro and in vivo. A natural compound disrupting the CPT1A–RAD51 interaction potently sensitized GBM to TMZ in vivo. Clinically, elevated RAD51 K156 succinylation correlated with poor prognosis and TMZ resistance. Conclusions We define a metabolic–epigenetic axis—TCA/succinyl-CoA/CPT1A/RAD51 K156 succinylation—that governs DNA repair and chemoresistance in GBM. CPT1A emerges as a therapeutic target, and RAD51 K156 succinylation serves as a promising prognostic biomarker for overcoming TMZ resistance.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: